



## J. B. CHEMICALS & PHARMACEUTICALS LIMITED

**REGD. OFFICE:**

"NEELAM CENTRE", 'B' WING, 4TH FLR.,  
HIND CYCLE ROAD, WORLI,  
MUMBAI - 400 030.

PHONE : 022-2482 2222 / 2493 0918

FAX : 022-2493 0534 / 2493 9633

e-mail : info@jbcpl.com

Website : www.jbcpl.com

CIN : L24390MH1976PLC019380

StockExchange-NSE letters/MM:SA:568

August 5, 2015

National Stock Exchange of India Ltd.  
Exchange Plaza, 5<sup>th</sup> floor,  
Plot no.C/1, 'G' Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai 400 051.

**Stock Symbol: JBCHEPHARM**

Dear Sir,

**Sub : Press Release**

Enclosed is a press release we propose to issue on unaudited financial results for the quarter ended on June 30, 2015.

Kindly take the same on record.

Thanking you,

Yours faithfully,  
for J.B. Chemicals & Pharmaceuticals Limited

M. C. Mehta  
Company Secretary and Vice President - Compliance

Encl: As above



## J. B. CHEMICALS & PHARMACEUTICALS LIMITED

**REGD. OFFICE:**

"NEELAM CENTRE", 'B' WING, 4TH FLR.,  
HIND CYCLE ROAD, WORLI,  
MUMBAI - 400 030.

PHONE : 022-2482 2222 / 2493 0918

FAX : 022-2493 0534 / 2493 9633

e-mail : info@jbcpl.com

Website : www.jbcpl.com

CIN : L24390MH1976PLC019380

### Press Release

BSE Scrip Code: 506943

NSE Symbol: JBCHEPHARM

Mumbai, August 5, 2015

### Unaudited Financial Results for Q 1- 2015-16

J.B. Chemicals & Pharmaceuticals Ltd. (JBCPL) today announced its standalone unaudited financial results for the quarter ended on June 30, 2015. The highlights of Y-o-Y results are as under:

| Particulars            | (Rs. in crores) |            |
|------------------------|-----------------|------------|
|                        | Q1-2015-16      | Q1-2014-15 |
| Net Sales              | 279.15          | 256.71     |
| Other Operating income | 5.05            | 5.89       |
| Other Income           | 4.30            | 1.74       |
| Total Income           | 288.50          | 264.34     |
| EBIDTA                 | 57.81           | 53.78      |
| Profit before tax      | 46.33           | 42.55      |
| Profit after tax       | 34.28           | 31.79      |
| EPS (Rs.) (FV 2)       | 4.04            | 3.75       |

The net sales for the quarter at Rs. 279.15 crores were 8.74% higher against net sales in the corresponding quarter in the previous year. The PBT and PAT for quarter at Rs. 46.33 and Rs. 34.28 crores were 8.88% and 7.83% higher respectively over corresponding quarter in the previous year.

The domestic formulations business at sales of Rs. 114.45 crores registered growth of 11.40%, while the focus products group continued to do well with growth of 19%. The contrast media products sales in domestic market at sales of Rs. 9.75 crores registered growth of 13.45%. The company continues to focus on cardiovascular products and topical preparations to drive the growth for the division during the year.

The overall formulations exports at Rs. 128 crores registered growth of 7.06% during the quarter. The exports of formulations to Rest of the world markets at Rs. 92.22 crores registered growth of 9.19% in Rupee terms. The company is currently making investments for the growth of this business particularly growth in the US market. Recently, the US FDA approved the company's ANDA for Lithium Carbonate Extended-release Tablets USP 300 mg. The company plans to commercialize this product in Q4 this year. The exports for Russia-CIS markets at Rs. 11.34 crores were lower YoY.



## J. B. CHEMICALS & PHARMACEUTICALS LIMITED

**REGD. OFFICE:**

"NEELAM CENTRE", 'B' WING, 4TH FLR.,  
HIND CYCLE ROAD, WORLI,  
MUMBAI - 400 030.

PHONE : 022-2482 2222 / 2493 0918

FAX : 022-2493 0534 / 2493 9633

e-mail : [info@jbcpl.com](mailto:info@jbcpl.com)

Website : [www.jbcpl.com](http://www.jbcpl.com)

CIN : L24390MH1976PLC019380

The API business with sales of Rs. 23.99 crores registered marginal growth.

### About JBCPL:

JBCPL, one of India's leading pharmaceutical companies, manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and APIs. JBCPL exports to many countries worldwide with a strong presence in Russia, Ukraine, CIS countries and South Africa. The Company continues to invest in growing its share in the regulated markets in USA, Europe and Australia. JBCPL has a strong R & D and regulatory set-up for development of new drug delivery system and formulations, filing of DMFs and ANDAs. Its State-of-the-Art manufacturing facilities are approved by health authorities of regulated markets.

For more information on JBCPL visit our website at [www.jbcpl.com](http://www.jbcpl.com). For more details, you may contact:

M.C. Mehta  
Company Secretary and Vice President- Compliance  
J. B. Chemicals & Pharmaceuticals Ltd.  
91 22 2482 2311

-- x --

### Forward Looking Statements:

*This Press Release may contain Forward Looking Statements regarding future events and future performance of J.B. Chemicals & Pharmaceuticals Ltd. that involve risks and uncertainties that could cause actual results to differ materially from those that may be indicated by such statements.*

*View*